Griffin Health, a leader in precision cancer care, recently launched a Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) Theranostics program in its Nuclear Medicine Department, expanding access to a groundbreaking treatment option for patients with advanced prostate cancer.
Developed by Novartis, Pluvicto is an FDA-approved radioligand therapy for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. This therapy targets prostate-specific membrane antigen (PSMA)-positive cancer cells, delivering a radioactive payload directly to the tumor, while minimizing damage to surrounding healthy tissue.
“With the launch of the Pluvicto Theranostics program, Griffin Health continues its commitment to bringing cutting-edge, evidence-based cancer care to our community, ensuring our patients have access to the most advanced treatments close to home,” said Griffin Health Vice President of Diagnostic and Cancer Services Christine Cooper, MS, CNMT, RT(N), RSO, FACHE, FAB. “This therapy revolutionizes personalized medicine and provides new hope for patients who have exhausted other treatment options.”
The Griffin Health Pluvicto Theranostics program is designed to expand access to a cutting-edge, targeted radioligand therapy, enhance coordination of care for men with advanced prostate cancer, and improve quality of life and potentially extend survival for eligible patients. It offers a person-centered multidisciplinary care model, including physicians in Nuclear Medicine, Medical Oncology, and Radiation Oncology as well as Nuclear Medicine Technologists, nursing staff, and patient navigation teams to ensure safe, effective, and personalized treatment delivery. As part of a continuous care model, Griffin Health offers PSMA PET/CT imaging for patients to confirm their eligibility before beginning therapy.
For more information, visit www.griffinhealth.org/pluvicto.
Griffin is now accepting referrals for its Pluvicto Theranostics program. Referring providers can contact the Nuclear Medicine Department at 203-732-7271 for more information and orders can be faxed to Central Scheduling at 203-732-1559.